Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Resminostat (4SC-201) in Combination With a Second-line Treatment in Patients With K-ras Mutated Advanced Colorectal Carcinoma

NCT01277406 is registered in ClinicalTrials.gov with 4SC AG as lead sponsor.

NCT NCT01277406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01277406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Resminostat (4SC-201) in Combination With a Second-line Treatment in Patients With K-ras Mutated Advanced Colorectal Carcinoma
Lead sponsor
4SC AG
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2011
Completion date
February 28, 2015
Enrollment
17 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal carcinoma